Ranolazine Effectively Ameliorated Brain Pathologies and Cognitive Decline in Rats with Trastuzumap‐Induced Chemobrain

Chemotherapy can increase survival rate of cancer patients. One of the chemotherapeutic drugs for breast cancer patients is trastuzumap (Trz). Chemotherapy not only helps to kill cancers, but it also causes several adverse effects in the patients, particularly in the brain, known as chemobrain. Chemobrain has been characterized by cognitive decline with brain mitochondrial dysfunction, hippocampal microglial activation, and loss of dendritic spines. Although several types of chemotherapy induce chemobrain, Trz‐induced chemobrain are not clearly elucidated. Ranolazine, a drug that is commonly used to treat the patients with chronic angina, shows benefits on cognitive function in doxorubicin‐induced chemobrain. However, the effects of ranolazine on brain mitochondrial function, hippocampal microglial function, hippocampal dendritic spines, and cognitive function in Trz‐induced chemobrain have never been investigated.